Novavax COVID-19 vaccine explained

Type:vaccine
Target:SARS-CoV-2
Vaccine Type:subunit
Tradename:Covovax, Nuvaxovid[1]
Dailymedid:Novavax
Pregnancy Au:B1
Pregnancy Au Comment:[2] [3]
Routes Of Administration:Intramuscular
Atc Prefix:J07
Atc Suffix:BN05
Legal Au:S4
Legal Au Comment:[4] [5] [6] [7] [8] [9]
Legal Ca:Rx-only
Legal Ca Comment:/ Schedule D[10] [11] [12] [13] [14]
Legal Uk:POM
Legal Us:Rx-only
Legal Us Comment:with standing order;[15] Unapproved (Emergency Use Authorization) for those aged 12+[16] [17] [18] [19] [20]
Legal Eu:Rx-only
Legal Status:Full list of Novavax vaccine authorizations
Drugbank:DB15810
Kegg:D12336
Unii:UK9AK2IN1P

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax,[21] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).[22]

Medical uses

The Novavax COVID19 vaccine is indicated for active immunization to prevent COVID19 caused by SARS-CoV-2.

Efficacy

A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval.[23] Efficacy is closely related to effectiveness, which is generally expected to slowly decrease over time.[24]

In December 2021, Novavax reported that its phase III trial showed the vaccine achieved its primary endpoint of preventing infection at least seven days after the second dose. Overall efficacy against different SARS-CoV-2s was 90.4% and efficacy against moderate-to-severe disease was 100%.[25] [26] Trials were conducted before the emergence of the SARS-CoV-2 Omicron variant, which has sharply reduced the effectiveness of authorized vaccines in preventing infections.

Side effects

The most common side effects include fever, headache, nausea, muscle and joint pain, tenderness and pain at the injection site, tiredness, and feeling unwell.

Additional possible side effects include anaphylaxis (severe allergic reaction), paresthesia (unusual feeling in the skin, such as tingling or a crawling sensation) and hypoesthesia (decreased feeling or sensitivity, especially in the skin), and pericarditis (inflammation of lining around the heart). It has also been reported that myocarditis (inflammation of heart muscle cells) as reported incidence from receiving the NVX-CoV2373 vaccine.[27]

On 27 January 2023, Australia's Therapeutic Goods Administration indicated it will add tinnitus to its label.[28]

Handling and administration

The vaccine requires two doses and is stable at 2C8C refrigerated temperatures. The second dose can be administered three to eight weeks apart from the first dose.[29] The vaccine injection can be administered intramuscularly (ie. deltoid, upper thigh, or upper buttock). There are currently no drug interaction that may affect the vaccine's efficacy if administered with other vaccines at the same time.

Pregnancy and breastfeeding

It is recommended that pregnant individuals, and those planning to get pregnant in the future, to get their COVID-19 vaccines updated . The vaccine is a recombinant protein, not a live virus, therefore it will not replicate and spread to the infant.[30] The patient should weigh the potential risks and complications if they decided to not get the virus due to insufficient data in pregnancy compared to being vaccinated for protection against the SARS-CoV-2 infection.

There are no studies conducted to trial the efficacy and safety of Novavax vaccine to patients who are breastfeeding. Since Novavax is not a live virus, it can be extrapolated that the vaccine will not replicate and concentrate in the breast milk.

Technology

NVX-CoV2373 has been described as both a protein subunit vaccine[31] [32] and a virus-like particle vaccine,[33] [34] though the producers call it a "recombinant nanoparticle vaccine".[35] By engineering the nanoparticle to contain the virus spike protein as the antigen, it allows the immune cells to easily recognize the antigen as the target protein. [36]

The vaccine is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.[37] The spike protein was modified by incorporating two proline amino acids in order to stabilize the pre-fusion form of the protein; this same 2P modification is being used in several other COVID19 vaccines.[38] The baculovirus is made to infect a culture of Sf9 moth cells, which then create the spike protein and display it on their cell membranes. The spike proteins are harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins.

The formulation includes a saponin-based adjuvant named Matrix-M.

Matrix-M adjuvant source is purified from Quillaja Saponaria Molina Tree. Matrix-M adjuvant is combined with the spike protein from the SARS-CoV-2 antigen to induce immune response in body upon vaccination. The adjuvant primarily enhances local antibodies and immunity at the local site of injection and draining lymph nodes. The adjuvant demonstrates its protection against the virus by inducing innate immune system rapidly. At the local site of injection, the adjuvant recruits antigen presenting cells and attracts more T cells, such as CD4+ and CD8+ T cells. After entry of the vaccine nanoparticle containing the recombinant spike protein of the virus, it binds to ACE2 (angiotensin-converting enzyme 2) receptor to allow endocytosis and viral replication. However, upon endocytosis these viral particles are digested by lysosome and presented to MHC class molecules. This will lead to attracting T cells (CD4+ and CD8+). This chemokine activity is further enhanced by the presence of the adjuvant component to enhance immune response from the viral particle. The cascade of immune activation leads to immediate immune response to target the virus as well as creating memory B cells specific to the antigen that the virus have.[39] These memory B cells enhances our immune response by faster immune cell recognition of these subsequent viral exposure to the same antigen compared to the initial exposure.[40]

Manufacturing

In February 2021, Novavax partnered with Takeda to manufacture the vaccine in Japan, where its COVID19 vaccine candidate is known as TAK-019.[41]

Novavax signed an agreement with Serum Institute of India for mass scale production for developing and low-income countries.[42] In 2020 it was reported, that the vaccine would be manufactured in Spain[43] and in November 2021 it was reported to be produced in Poland by the Mabion company.[44] As of 2021, antigens were made at Novavax's factory Novavax CZ in the Czech Republic;[45] Novavax CZ was also marketing authorisation holder of its EU authorization.[46]

In May 2021, Serum Institute of India said that it started the production of the Novavax COVID19 vaccine candidate branded as Covovax in India after receiving permission from the Indian government.[47]

History

In January 2020, Novavax announced development of a vaccine candidate, codenamed NVX-CoV2373, to establish immunity to SARS-CoV-2.[48] Novavax's work is in competition for vaccine development among dozens of other companies.[49]

In March 2020, Novavax announced a collaboration with Emergent BioSolutions for preclinical and early-stage human research on the vaccine candidate.[50] Under the partnership, Emergent BioSolutions was supposed to manufacture the vaccine at large scale at their Baltimore facility.[51] However, following production issues with the Johnson & Johnson and Oxford–AstraZeneca vaccines at its Baltimore plant and to decrease the burden on the plant, Novavax subsequently partnered with a different manufacturer in a new agreement overseen by the U.S. government.[52]

Trials have also taken place in the United Kingdom.[53] [54] The first human safety studies of the candidate, codenamed NVX-CoV2373, started in May 2020 in Australia.[55] [56]

In July 2020, the company announced it might receive from Operation Warp Speed to expedite development of its coronavirus vaccine candidate by 2021if clinical trials show the vaccine to be effective.[57] A spokesperson for Novavax stated that the $1.6 billion was coming from a "collaboration" between the Department of Health and Human Services and Department of Defense.[58]

Novavax announced a deal with Sanofi in 2024, with Sanofi taking over commercialization responsibilities for NVX-CoV2373 in most countries starting in 2025.[59] The deal also allows them to use the vaccine and Matrix-M to develop new vaccine products.[60]

Clinical trials

Phase I and II

In May 2020, Australia's first human trials of a candidate COVID19 vaccine, Novavax's NVX-CoV2373, began in Melbourne. It involved about 130 volunteers aged between 18-59.[61]

Phase III

In September 2020, Novavax started for a phase III trial with 15,000 in the UK.[62] [63]

In December 2020, Novavax started the PREVENT-19 (NCT04611802) phase III trial in the US and Mexico, funded by NIAID and BARDA.[64]

In May 2021, Novavax initiated a pediatric expansion for the phase III clinical trial, with 3,000 adolescents 12–17 years of age in up to 75 sites in the United States.[65]

UK trial

In January 2021, Novavax reported that preliminary results from the United Kingdom trial showed that its vaccine candidate was more than 89% effective.[66] [67]

The Thackray Museum of Medicine in Leeds hosted the largest cohort of volunteers. Trials of the Novavax vaccine were conducted on 5,000 people there during 2021.[68]

In June 2021, a primary Novavax-funded study found that the vaccine has an overall efficacy of 83.4% two weeks after the first dose and 89.7% one week after the second dose. A post hoc analysis showed an efficacy of 86.3% against the B.1.1.7 (Alpha) variant and 96.4% against "non-B.1.1.7 strains", the majority of which were the "prototype strains" (original strain).[69] [70]

South Africa trial

In January 2021, Novavax reported that interim results from a trial in South Africa showed a lower effectiveness rate against the Beta variant (lineage B.1.351), at around 50–60%.[71] [72]

In a study reported in March and May 2021, the efficacy of the Novavax vaccine (NVX-CoV2373) was tested in a preliminary randomized, placebo-controlled study involving 2684 participants who were negative for COVID at baseline testing. The Beta variant was the predominant variant to occur, with post-hoc analysis indicating a cross-protective vaccine efficacy of Novavax against Beta of 51.0% for HIV-negative participants.[37] [73]

US and Mexico trial

In June 2021, Novavax announced overall 90.4% efficacy in the phase III US & Mexico trial that involved nearly 30,000 people aged 18 years of age and older.[74] From the total 77 COVID-19 cases found in the trial participants, 14 occurred in the vaccine group, while 63 occurred in the placebo group.[75]

Administration

About 216,000 doses of the Novavax COVID-19 vaccine were administered in the EU/EEA from authorization to 26 June 2022.[76]

Legal status

In February 2021, the European Medicines Agency (EMA) started a rolling review of the Novavax COVID-19 vaccine (NVX‑CoV2373). In November 2021, the EMA received application for conditional marketing authorization.[77] In December 2021, the European Commission granted a conditional marketing authorization across the EU, following a recommendation from the EMA, for it to be sold under the brand name Nuvaxovid.[78] [79] [80]

As of November 2021, it has been authorized for use in Indonesia,[81] the Philippines,[82] as of December in India,[83] as of January 2022 in South Korea,[84] [85] Australia,[86] [87] as of February 2022 in the United Kingdom,[88] Canada,[89] Taiwan,[90] and Singapore.[91] [92] As of December 2021 it was validated by the World Health Organization.[93]

In June 2022, the FDA's advisory committee voted 21-0 with one abstention to recommend authorization of Novavax's vaccine for use in adults in the United States.[94] [95] In July 2022, the FDA authorized NVX-CoV2373 for emergency use as a primary immunization (not booster) in adults.[96] making it the fourth COVID19 vaccine authorized in the US.[97] In July 2022, the US Centers for Disease Control and Prevention (CDC) recommended the Novavax COVID19 vaccine as a two-dose primary series for adults age 18 and older, thus endorsing the recommendation from the Advisory Committee on Immunization Practices (ACIP) regarding this vaccine.[98] [99] In August 2022, the FDA granted Emergency Use Authorization for the Novavax COVID19 vaccine in people aged 12–17 years.[19] In August 2022, the CDC recommended the Novavax COVID19 vaccine for adolescents aged 12–17 years.[100]

In October 2023, the FDA amended the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the Novavax COVID-19 Vaccine, Adjuvanted (2023–2024 Formula) and removed the authorization for the Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent).[101] [102]

Further reading

External links

Notes and References

  1. Web site: 3 February 2022. Regulatory approval of COVID-19 vaccine Nuvaxovid. 3 February 2022. Medicines and Healthcare products Regulatory Agency (MHRA). 3 February 2022. https://web.archive.org/web/20220203113406/https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-nuvaxovid. live.
  2. Web site: Nuvaxovid APMDS . Therapeutic Goods Administration (TGA) . 20 January 2022 . 5 February 2022 . 5 February 2022 . https://web.archive.org/web/20220205220734/https://www.tga.gov.au/apm-summary/nuvaxovid . live .
  3. Web site: Updates to the Prescribing Medicines in Pregnancy database . Therapeutic Goods Administration (TGA) . 12 May 2022 . 13 May 2022 . 3 April 2022 . https://web.archive.org/web/20220403064059/https://www.tga.gov.au/updates-prescribing-medicines-pregnancy-database . live .
  4. Web site: TGA eBS - Product and Consumer Medicine Information Licence. 5 February 2022. 5 February 2022. https://web.archive.org/web/20220205224032/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2022-PI-01041-1. live.
  5. Web site: AusPAR: SARS-CoV-2 rS with Matrix-M adjuvant . Therapeutic Goods Administration (TGA) . 21 January 2022 . 23 March 2022 . 24 March 2022 . https://web.archive.org/web/20220324051943/https://www.tga.gov.au/auspar/auspar-sars-cov-2-rs-matrix-m-adjuvant . live .
  6. Web site: AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant . Therapeutic Goods Administration (TGA) . 27 June 2022 . 17 July 2022 . 16 July 2022 . https://web.archive.org/web/20220716111533/https://www.tga.gov.au/auspar/auspar-sars-cov-2-rs-vaccine-matrix-m1-adjuvant-0 . live .
  7. Web site: AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant . Therapeutic Goods Administration (TGA) . 24 June 2022 . 17 July 2022 . 16 July 2022 . https://web.archive.org/web/20220716112641/https://www.tga.gov.au/auspar/auspar-sars-cov-2-rs-vaccine-matrix-m1-adjuvant . live .
  8. Web site: Novavax) (Biocelect Pty Ltd) Labelling Exemption 2022 . Therapeutic Goods Administration (TGA) . 21 June 2022 . 9 April 2023 . 19 March 2023 . https://web.archive.org/web/20230319233842/https://www.tga.gov.au/therapeutic-goods-poisons-standard-covid-19-vaccine-novavax-biocelect-pty-ltd-labelling-exemption-2022 . live .
  9. Web site: Nuvaxovid . Australian Public Assessment Report (AusPAR) . The Department of Health and Aged Care, Australian Government .
  10. Web site: Product Monograph, NUVAXOVID ™, COVID-19 Vaccine (Recombinant protein, Adjuvanted) . Novavax, Inc. . 24 March 2022 . 14 July 2022 . 29 May 2022 . https://web.archive.org/web/20220529065717/https://pdf.hres.ca/dpd_pm/00065155.PDF . live .
  11. Web site: Novavax Nuvaxovid COVID-19 vaccine . . 17 February 2022 . 29 May 2022 . 29 May 2022 . https://web.archive.org/web/20220529181252/https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html . live .
  12. Web site: Summary Basis of Decision (SBD) for Nuvaxovid . . 23 October 2014 . 29 May 2022 . 29 May 2022 . https://web.archive.org/web/20220529182848/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00581&lang=en . live .
  13. Web site: Nuvaxovid . . 17 February 2022 . 31 May 2022 . 1 June 2022 . https://web.archive.org/web/20220601041156/https://covid-vaccine.canada.ca/nuvaxovid/product-details . live .
  14. Web site: Summary Basis of Decision (SBD) for Nuvaxovid XBB.1.5 . . 9 February 2024 . 24 February 2024.
  15. Web site: Novavax COVID-19 Vaccine: Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older . . 22 August 2022 . 3 September 2022 . 3 August 2022 . https://web.archive.org/web/20220803231308/https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-standing-orders.pdf . live .
  16. Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted . . 13 July 2022 . 15 July 2022 . 15 July 2022 . https://web.archive.org/web/20220715003957/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted . live .
  17. Web site: Novavax COVID-19 Vaccine . U.S. Food and Drug Administration . 13 July 2022 . 15 July 2022 . 14 July 2022 . https://web.archive.org/web/20220714200333/https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted . live .
  18. Web site: Novavax HCP Fact Sheet 07132022 . Novavax, Inc. . . 13 July 2022 . 15 July 2022 . 14 July 2022 . https://web.archive.org/web/20220714112543/https://www.fda.gov/media/159897/download . live .
  19. FDA Roundup: August 19, 2022 . U.S. Food and Drug Administration . 19 August 2022 . 20 August 2022 . 21 August 2022 . https://web.archive.org/web/20220821045136/https://www.fda.gov/news-events/press-announcements/fda-roundup-august-19-2022 . live .
  20. Web site: Novavax COVID-19 Vaccine, Adjuvanted- nvx-cov2373 injection, suspension . DailyMed . 11 October 2023 . 18 December 2023.
  21. News: WHO issues emergency use listing to Novavax-Serum Institute's COVID-19 vaccine . Reuters . 17 December 2021 . 17 December 2021 . 17 December 2021 . https://web.archive.org/web/20211217150639/https://www.reuters.com/business/healthcare-pharmaceuticals/who-issues-emergency-use-listing-novavax-serum-institutes-covid-19-vaccine-2021-12-17/ . live .
  22. News: Leo L . Hope to launch Covovax by September, says Serum Institute CEO . 28 March 2021 . mint . 27 March 2021 . 13 May 2021 . https://web.archive.org/web/20210513082056/https://www.livemint.com/companies/news/hope-to-launch-covovax-by-september-says-serum-institute-ceo-11616834205232.html . live.
  23. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, Halloran ME, Huang Y, Fleming TR, Gilbert PB, DeGruttola V . 12 September 2020 . COVID-19 vaccine trials should seek worthwhile efficacy . The Lancet . 396 . 10253 . 741–743 . 10.1016/S0140-6736(20)31821-3 . 0140-6736 . 32861315 . 7832749 . WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure. . secondary .
  24. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP . May 2021 . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection . Nature Medicine . 27 . 7 . 1205–1211 . 10.1038/s41591-021-01377-8 . 1546-170X . 34002089 . 234769053 . free . doi . primary .
  25. Web site: What Happened to the Novavax Vaccine? . MedPage Today . Henderson J . 1 January 2022 . 5 February 2022 . 7 February 2022 . https://web.archive.org/web/20220207120232/https://www.medpagetoday.com/special-reports/exclusives/96461 . live .
  26. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico . December 2021 . Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F . New England Journal of Medicine . 34910859 . 8693692 . 10.1056/NEJMoa2116185 . free . doi . 386 . 6 . 531–543 . primary .
  27. Web site: Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C . 30 June 2021 . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine . 21 April 2024 . login.uml.idm.oclc.org.
  28. Web site: Therapeutic Goods Administration . 27 January 2023 . COVID-19 vaccine safety report - 27-01-2023 . 31 January 2023 . 31 January 2023 . https://web.archive.org/web/20230131215241/https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-safety-report-27-01-2023 . live .
  29. Web site: Crawley A, LeBras M, Regier L . February 2024 . COVID-19 PREVENTION . 19 April 2024 . Rxfiles.
  30. Web site: COVID-19 Protein Subunit Vaccine (Novavax) . Mother To Baby Fact Sheets [Internet] . Brentwood (TN) . Organization of Teratology Information Specialists (OTIS) . May 2023 .
  31. Wadman M . The long shot . Science . 370 . 6517 . 649–653 . November 2020 . 33154120 . 10.1126/science.370.6517.649 . doi . 2020Sci...370..649W. 226270339 . comment .
  32. Wadman M . 28 December 2020 . Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays . Science . 10.1126/science.abg3441. 234411557 . doi .
  33. Chung YH, Beiss V, Fiering SN, Steinmetz NF . COVID-19 Vaccine Frontrunners and Their Nanotechnology Design . ACS Nano . 14 . 10 . 12522–12537 . October 2020 . 33034449 . 7553041 . 10.1021/acsnano.0c07197 . secondary .
  34. Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D . Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles . ACS Nano . 14 . 6 . 7617–7627 . June 2020 . 7482545 . 10.1021/acsanm.0c01978 . 32437124 . primary .
  35. Web site: Urgent global health needs addressed by Novavax . 30 January 2021 . Novavax. 12 May 2021. https://web.archive.org/web/20210512090816/https://www.novavax.com/our-unique-technology. live.
  36. Web site: A New Era of Vaccines for Canada Novavax . 1 May 2024 . ca.novavax.com . en.
  37. Hotez PJ, Bottazzi ME . Whole Inactivated Virus and Protein-Based COVID-19 Vaccines . Annual Review of Medicine . 73 . 1 . 55–64 . January 2022 . 34637324 . 10.1146/annurev-med-042420-113212 . 238747462 . free . secondary .
  38. News: Zimmer C . 5 April 2021 . Researchers Are Hatching a Low-Cost Coronavirus Vaccine . . 23 April 2021 . 0362-4331. 28 April 2021. https://web.archive.org/web/20210428135245/https://www.nytimes.com/2021/04/05/health/hexapro-mclellan-vaccine.html. live.
  39. Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, Carnrot C, Shinde V, Smith G, Glenn G, Fries L, Lövgren Bengtsson K . The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century . Human Vaccines & Immunotherapeutics . 19 . 1 . 2189885 . December 2023 . 37113023 . 10158541 . 10.1080/21645515.2023.2189885 . primary .
  40. Majumder J, Minko T . Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 . The AAPS Journal . 23 . 1 . 14 . January 2021 . 33400058 . 7784226 . 10.1208/s12248-020-00532-2 . secondary .
  41. Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan . 11 March 2021 . Takeda . 24 February 2021 . 24 February 2021 . https://web.archive.org/web/20210224074427/https://www.takeda.com/newsroom/newsreleases/2021/takeda-provides-updates-on-phase-12-clinical-trials-of--novavax-and-modernas-covid-19-vaccine-candidates-in-japan/ . live.
  42. News: 5 August 2020. Novavax signs COVID-19 vaccine supply deal with India's Serum Institute. Reuters. live. 21 February 2021. https://web.archive.org/web/20210319014912/https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-signs-covid-19-vaccine-supply-deal-with-indias-serum-institute-idINKCN25139A. 19 March 2021.
  43. Web site: 18 September 2020. Spain, again chosen to produce the vaccine to combat COVID-19. dead. https://web.archive.org/web/20210319015957/https://www.thisistherealspain.com/en/latest-news/spain-again-chosen-to-produce-the-vaccine-to-combat-covid-19/. 19 March 2021. 29 January 2021. This is the Real Spain. Secretariat of State for Global Spain, Spanish Ministry of Foreign Affairs.
  44. News: 25 March 2021. Novavax Deal With Mabion Boosts Poland's Nascent Biotech Scene. live. https://web.archive.org/web/20210309181639/https://www.bloomberg.com/news/articles/2021-03-03/novavax-deal-with-mabion-boosts-poland-s-nascent-biotech-scene. 9 March 2021. 24 March 2021. Bloomberg. Bujnicki P, Krasuski K.
  45. Web site: EU approves Novavax shot as fifth COVID vaccine. 21 December 2021. Al Jazeera English. 21 December 2021. https://web.archive.org/web/20211221012257/https://www.aljazeera.com/news/2021/12/20/eu-approves-novavax-shot-as-fifth-covid-vaccine. live.
  46. Web site: Nuvaxovid EPAR . 17 December 2021 . European Medicines Agency (EMA) . 23 December 2021 . 23 December 2021 . https://web.archive.org/web/20211223093752/https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  47. News: 26 May 2021. SII begins manufacturing, stockpiling 2nd Covid vaccine Covovax after Modi govt nod. ThePrint. live. 29 May 2021. https://web.archive.org/web/20210529143626/https://theprint.in/health/sii-begins-manufacturing-stockpiling-2nd-covid-vaccine-covovax-after-modi-govt-nod/665600/. 29 May 2021. Chandna H.
  48. News: Gilgore S . Novavax is working to advance a potential coronavirus vaccine. So are competitors. . Washington Business Journal . 6 March 2020 . 26 February 2020 . 16 March 2020 . https://web.archive.org/web/20200316041227/https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html . live.
  49. Web site: COVID-19 vaccine tracker (click on 'Vaccines' tab) . Milken Institute . 12 May 2020 . 11 May 2020 . 6 June 2020 . https://web.archive.org/web/20200606220149/https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/htmlview?pru=AAABchldaXU*ZWdU7a75RG6u_cw8QpEBhw . live.
  50. News: Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions . Gilgore S . 10 March 2020 . Washington Business Journal. 10 March 2020. 9 April 2020. https://web.archive.org/web/20200409200636/https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html. live.
  51. News: McCartney R . Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine . . 4 May 2020 . live. https://web.archive.org/web/20200507230732/https://www.washingtonpost.com/local/maryland-plays-an-outsized-role-in-worldwide-hunt-for-a-coronavirus-vaccine/2020/05/03/3b6f2cb8-8bd5-11ea-8ac1-bfb250876b7a_story.html. 7 May 2020. 8 May 2020.
  52. News: Stolberg SG, LaFraniere S, Hamby C . Top Official Warned That Covid Vaccine Plant Had to Be 'Monitored Closely' . 6 May 2021 . . 7 April 2021 . 6 May 2021 . https://web.archive.org/web/20210506013857/https://www.nytimes.com/2021/04/07/us/emergent-biosolutions-coronavirus-vaccine.html . live.
  53. News: Novavax Covid vaccine shown to be nearly 90% effective in UK trial . Boseley S, Davis N . The Guardian . 28 January 2021 . 29 January 2021 . 12 April 2021 . https://web.archive.org/web/20210412163928/https://www.theguardian.com/society/2021/jan/28/novavax-covid-vaccine-shown-to-be-nearly-90-effective-in-uk-trial . live.
  54. News: 60m doses of new covid-19 vaccine could be made in Billingham – and be ready for mid-2021 . Brown M . Teesside News . 14 August 2020 . 29 January 2021 . 7 February 2021 . https://web.archive.org/web/20210207060752/https://www.gazettelive.co.uk/news/teesside-news/60m-doses-new-covid-19-18767512 . live.
  55. News: Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work . Sagonowsky E . FiercePharma . 11 May 2020. 12 May 2020. 16 May 2020. https://web.archive.org/web/20200516215744/https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work. live.
  56. Web site: Novavax starts clinical trial of its coronavirus vaccine candidate . 25 May 2020 . CNBC . 26 May 2020. 26 May 2020. https://web.archive.org/web/20200526013622/https://www.cnbc.com/2020/05/25/novavax-starts-phase-1-clinical-trial-of-coronavirus-vaccine-candidate.html. live.
  57. News: Steenhuysen J . 7 July 2020 . U.S. government awards Novavax $1.6 billion for coronavirus vaccine . Reuters . 15 September 2020. 14 September 2020. https://web.archive.org/web/20200914213046/https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKBN248182. live.
  58. News: U.S. Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine . The New York Times . Thomas K . 7 July 2020. 7 July 2020. 7 July 2020. https://web.archive.org/web/20200707101003/https://www.nytimes.com/2020/07/07/health/novavax-coronavirus-vaccine-warp-speed.html. live.
  59. Web site: Dunleavy . Kevin . 2024-05-10 . Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform . 2024-08-06 . Fierce Pharma.
  60. Web site: Joseph . Andrew . 2024-05-10 . Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline . 2024-08-06 . STAT . en-US.
  61. News: Human trials of potential coronavirus vaccine begin in Melbourne . 27 July 2021 . Australian Broadcasting Corporation . 25 May 2020 . 2 June 2021 . https://web.archive.org/web/20210602050609/https://www.abc.net.au/news/2020-05-26/coronavirus-vaccine-trial-begins-in-melbourne-brisbane/12286028 . live .
  62. News: Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom . 14 August 2021 . Novavax . 24 September 2020 . 14 August 2021 . https://web.archive.org/web/20210814003420/https://ir.novavax.com/2020-09-24-Novavax-Initiates-Phase-3-Efficacy-Trial-of-COVID-19-Vaccine-in-the-United-Kingdom . live .
  63. Web site: A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom . United States National Library of Medicine . 13 August 2020 . 12 October 2021 . live . 25 May 2021 . https://web.archive.org/web/20210525193308/https://clinicaltrials.gov/ct2/show/NCT04583995 .
  64. Phase 3 trial of Novavax investigational COVID-19 vaccine opens . National Institutes of Health (NIH) . 28 December 2020 . 28 December 2020 . 19 January 2021 . https://web.archive.org/web/20210119074047/https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens . live.
  65. Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine . 30 May 2021 . Novavax . 3 May 2021 . 2 June 2021 . https://web.archive.org/web/20210602213316/https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-pediatric-expansion-phase-3-clinical-trial . dead.
  66. News: Lovelace B . 28 January 2020 . Novavax says Covid vaccine is more than 89% effective . CNBC . 28 January 2021. 30 January 2021. https://web.archive.org/web/20210130124318/https://www.cnbc.com/2021/01/28/covid-vaccine-novavax-says-covid-vaccine-is-more-than-89percent-effective.html. live.
  67. News: 28 January 2021 . New Covid vaccine shows 89% efficacy in UK trials . BBC News . 28 January 2021. 30 January 2021. https://web.archive.org/web/20210130035901/https://www.bbc.com/news/uk-55850352. live.
  68. Web site: Novavax COVID vaccine has been approved! - Thackray Museum of Medicine . 21 May 2024 . thackraymuseum.co.uk.
  69. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine . The New England Journal of Medicine . June 2021 . 385 . 13 . 1172–1183 . 34192426 . 10.1056/NEJMoa2107659 . 235697707 . 8262625 . free . doi . primary .
  70. Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine . 30 June 2021 . 30 June 2021 . Novavax . 30 June 2021. https://web.archive.org/web/20210630213332/https://ir.novavax.com/2021-06-30-Novavax-Publishes-Results-of-United-Kingdom-Phase-3-Clinical-Trial-in-New-England-Journal-of-Medicine,-Demonstrating-High-Levels-of-Efficacy-of-COVID-19-Vaccine?sf146717139=1. live.
  71. Wadman M, Jon C . Novavax vaccine delivers 89% efficacy against COVID-19 in UKbut is less potent in South Africa . Science . 28 January 2021 . 10.1126/science.abg8101 . doi . 234058820 .
  72. Web site: Facher L, Joseph A . Novavax says its Covid-19 vaccine is 90% effective in late-stage trial . . 28 January 2021 . 29 January 2021 . 29 January 2021 . https://web.archive.org/web/20210129235353/https://www.statnews.com/2021/01/28/novavax-says-its-covid-19-vaccine-is-90-effective-but-far-less-so-against-one-variant/ . live.
  73. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MS, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA . Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant . The New England Journal of Medicine . 384 . 20 . 1899–1909 . May 2021 . 33951374 . 8091623 . 10.1056/NEJMoa2103055 . primary .
  74. News: Johnson L . 14 June 2021 . Large study finds that vaccine maker Novavax's shot is about 90% effective . . 15 June 2021. 18 June 2021. https://web.archive.org/web/20210618091305/https://www.latimes.com/world-nation/story/2021-06-14/novavax-large-study-finds-novavax-covid-19-shot-about-90-effective?utm_id=31286&sfmc_id=1352782. live.
  75. News: Howard J . 14 June 2021 . Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial . . 14 June 2021. 14 June 2021. https://web.archive.org/web/20210614105122/https://edition.cnn.com/2021/06/14/health/novavax-covid-19-vaccine-us-phase-3-trial-study/index.html. live.
  76. Web site: COVID-19 vaccines safety update . 3 August 2022 . . 3 August 2022 . 3 August 2022 . https://web.archive.org/web/20220803225933/https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-14-july-2022_en.pdf . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  77. Web site: 17 November 2021. EMA receives application for conditional marketing authorisation of Novavax's COVID-19 vaccine, Nuvaxovid. live. European Medicines Agency (EMA). 5 December 2021. 1 December 2021. https://web.archive.org/web/20211201201348/https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-novavaxs-covid-19-vaccine-nuvaxovid.
  78. 20 December 2021. EMA recommends Nuvaxovid for authorisation in the EU. live. European Medicines Agency (EMA). 20 December 2021. 20 December 2021. https://web.archive.org/web/20211220140047/https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu.
  79. Web site: Nuvaxovid . Union Register of medicinal products . European Commission . 6 July 2022 . 23 December 2021 . 20 December 2021 . https://web.archive.org/web/20211220193907/https://ec.europa.eu/health/documents/community-register/html/h1618.htm . live .
  80. Web site: Nuvaxovid : EPAR - Product information . . 5 July 2022 . 11 August 2022 . 17 August 2022 . https://web.archive.org/web/20220817161517/https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf . live .
  81. News: 1 November 2021. Novavax COVID-19 vaccine receives first emergency use authorization . O'Donnell C, Nadeem D . Reuters. 1 November 2021. 24 December 2021. https://web.archive.org/web/20211224034919/https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-covid-19-vaccine-receives-emergency-use-authorization-indonesia-2021-11-01/. live.
  82. News: Philippines approves emergency use of Novavax's COVID-19 vaccine . 17 November 2021 . Reuters . 17 November 2021 . 23 December 2021 . https://web.archive.org/web/20211223012200/https://www.reuters.com/business/healthcare-pharmaceuticals/philippines-approves-emergency-use-novavaxs-covid-19-vaccine-2021-11-17/ . live .
  83. News: Achom D . India Clears 2 New Vaccines And Merck's Covid Pill . NDTV.com . 28 December 2021 . 28 December 2021 . 28 December 2021 . https://web.archive.org/web/20211228054125/https://www.ndtv.com/india-news/coronavirus-2-more-vaccines-covovax-and-corbevax-and-anti-viral-drug-molnupiravir-cleared-in-india-2675170 . live .
  84. News: Jeong A . 12 January 2022. South Korea approves Novavax coronavirus vaccine. live. https://web.archive.org/web/20220112110238/https://www.washingtonpost.com/world/2022/01/12/novavax-vaccine-south-korea-authorization-covid/. 12 January 2022. 15 January 2022. .
  85. News: 12 January 2022. S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills. Reuters. 16 January 2022. 15 January 2022. https://web.archive.org/web/20220115213852/https://www.reuters.com/business/healthcare-pharmaceuticals/skorea-authorises-use-novavax-covid-19-vaccine-2022-01-12/. live.
  86. TGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine Nuvaxovid . Therapeutic Goods Administration (TGA) . 19 January 2022 . 5 February 2022 . 28 January 2022 . https://web.archive.org/web/20220128170700/https://www.tga.gov.au/media-release/tga-provisionally-approves-novavax-biocelect-pty-ltds-covid-19-vaccine-nuvaxovid . live .
  87. TGA approves provisional determination for Biocelect Pty Ltd for COVID-19 vaccine, Nuvaxovid . Therapeutic Goods Administration (TGA) . 10 March 2022 . 7 May 2022 . 8 May 2022 . https://web.archive.org/web/20220508042219/https://www.tga.gov.au/media-release/tga-approves-provisional-determination-biocelect-pty-ltd-covid-19-vaccine-nuvaxovid . live .
  88. News: 3 February 2022. Novavax Covid jab approved by UK drugs regulator . Reed J . BBC News. 3 February 2022. 3 February 2022. https://web.archive.org/web/20220203133857/https://www.bbc.com/news/health-60245736. live.
  89. Health Canada. 17 February 2022. Ottawa. Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine. 17 February 2022. 17 February 2022. https://web.archive.org/web/20220217170449/https://www.canada.ca/en/health-canada/news/2022/02/health-canada-authorizes-novavaxs-nuvaxovid-covid-19-vaccine.html. live.
  90. Web site: 23 June 2022. Novavax's COVID-19 shot authorized in Taiwan for adults. 23 June 2022. Reuters. 2 July 2022. https://web.archive.org/web/20220702090308/https://www.reuters.com/business/healthcare-pharmaceuticals/novavaxs-covid-19-shot-authorized-taiwan-adults-2022-06-23/. live.
  91. Web site: Chong C . Novavax Covid-19 vaccine approved for those aged 18 and above in Singapore . The Straits Times . 6 March 2022 . 14 February 2022 . 9 March 2022 . https://web.archive.org/web/20220309034414/https://www.straitstimes.com/singapore/novavax-covid-19-vaccine-approved-for-those-aged-18-and-above-to-arrive-in-the-next-few-months . live .
  92. Web site: Andres G . Novavax's Nuvaxovid COVID-19 vaccine granted interim authorisation in Singapore . . 6 March 2022 . 14 February 2022 . 11 March 2022 . https://web.archive.org/web/20220311020241/https://www.channelnewsasia.com/singapore/novavax-nuvaxovid-covid-19-vaccine-interim-authorisation-singapore-hsa-2496476 . live .
  93. WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries . World Health Organization (WHO) . 17 December 2021 . 17 December 2021 . 24 December 2021 . https://web.archive.org/web/20211224142249/https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries . live .
  94. Web site: Kimball S . 9 June 2022 . FDA decision on Novavax's Covid shots could be delayed to review changes in manufacturing . 9 June 2022 . CNBC . 9 June 2022 . https://web.archive.org/web/20220609123101/https://www.cnbc.com/2022/06/09/fda-decision-on-novavaxs-covid-shots-could-be-delayed-.html . live .
  95. News: Khemlani A . 7 June 2022 . FDA advisory committee recommends Novavax vaccine for use in adults . . 9 June 2022 . 9 June 2022 . https://web.archive.org/web/20220609123101/https://finance.yahoo.com/news/fda-advisory-committee-recommends-novavax-vaccine-for-use-in-adults-194314939.html . live .
  96. Web site: Christensen J, Goodman B . FDA gives emergency use authorization to Novavax's Covid-19 vaccine . 13 July 2022 . 14 July 2022 . CNN . 14 July 2022 . https://web.archive.org/web/20220714120922/https://www.cnn.com/2022/07/13/health/novavax-covid-vaccine-fda-authorization/index.html . live .
  97. News: Robbins R, Zimmer C . 19 July 2022 . A fourth Covid vaccine is cleared for use in the United States . The New York Times . 21 July 2022 . 0362-4331 . 21 July 2022 . https://web.archive.org/web/20220721041002/https://www.nytimes.com/2022/07/19/health/cdc-novavax-covid-vaccine.html . live .
  98. CDC Recommends Novavax's COVID-19 Vaccine for Adults . . 19 July 2022 . 21 July 2022 . 20 July 2022 . https://web.archive.org/web/20220720172739/https://www.cdc.gov/media/releases/2022/s0719-covid-novavax-vaccine.html . live .
  99. News: Neergaard L . 19 July 2022 . CDC endorses more traditional Novavax COVID shot for adults . . 21 July 2022 . 22 July 2022 . https://web.archive.org/web/20220722001047/https://apnews.com/article/covid-science-health-centers-for-disease-control-and-prevention-29202c59952b4454079c36ce589eaa7b . live .
  100. CDC Recommends Novavax COVID-19 Vaccine for Adolescents . . 22 August 2022 . 3 September 2022 . 3 September 2022 . https://web.archive.org/web/20220903072230/https://www.cdc.gov/media/releases/2022/s0822-novax-vaccine.html . live .
  101. FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants . U.S. Food and Drug Administration (FDA) . 3 October 2023 . 4 October 2023 . 4 October 2023 . https://web.archive.org/web/20231004030327/https://www.fda.gov/news-events/press-announcements/fda-authorizes-updated-novavax-covid-19-vaccine-formulated-better-protect-against-currently . live .
  102. Web site: Novavax COVID-19 Vaccine, Adjuvanted . U.S. Food and Drug Administration (FDA) . 3 October 2023 . 4 October 2023 . 4 October 2023 . https://web.archive.org/web/20231004024719/https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Novavax COVID-19 vaccine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.